{"result": "(\"entity\"<|>URINARY BLADDER CANCER<|>EVENT<|>Urinary Bladder Cancer is a type of disease characterized by various symptoms and localizations within the human body.)\n##\n(\"entity\"<|>ANOREXIA<|>EVENT<|>Anorexia is a symptom associated with Urinary Bladder Cancer, indicating a loss of appetite.)\n##\n(\"entity\"<|>URINARY BLADDER, NEUROGENIC<|>EVENT<|>Neurogenic urinary bladder is a symptom of Urinary Bladder Cancer affecting bladder function.)\n##\n(\"entity\"<|>BODY WEIGHT<|>EVENT<|>Changes in body weight are a symptom associated with Urinary Bladder Cancer.)\n##\n(\"entity\"<|>DIARRHEA<|>EVENT<|>Diarrhea is a symptom that can occur in patients with Urinary Bladder Cancer.)\n##\n(\"entity\"<|>EDEMA<|>EVENT<|>Edema is a symptom that may present in individuals with Urinary Bladder Cancer, indicating swelling due to fluid retention.)\n##\n(\"entity\"<|>FEVER<|>EVENT<|>Fever is a common symptom that can be associated with Urinary Bladder Cancer.)\n##\n(\"entity\"<|>FLATULENCE<|>EVENT<|>Flatulence is a symptom that may occur in patients suffering from Urinary Bladder Cancer.)\n##\n(\"entity\"<|>NAUSEA<|>EVENT<|>Nausea is a symptom that can be experienced by individuals with Urinary Bladder Cancer.)\n##\n(\"entity\"<|>PAIN, POSTOPERATIVE<|>EVENT<|>Postoperative pain can be a symptom related to treatments for Urinary Bladder Cancer.)\n##\n(\"entity\"<|>PARAPLEGIA<|>EVENT<|>Paraplegia is a severe symptom that may be associated with complications from Urinary Bladder Cancer.)\n##\n(\"entity\"<|>LYMPH NODE<|>GEO<|>Lymph nodes are one of the localizations where Urinary Bladder Cancer can manifest.)\n##\n(\"entity\"<|>URETER<|>GEO<|>The ureter is a part of the human body where Urinary Bladder Cancer can localize.)\n##\n(\"entity\"<|>URETHRA<|>GEO<|>The urethra is another localization site for Urinary Bladder Cancer.)\n##\n(\"entity\"<|>FEMALE REPRODUCTIVE SYSTEM<|>GEO<|>The female reproductive system can be affected by Urinary Bladder Cancer.)\n##\n(\"entity\"<|>BASAL LAMINA OF EPITHELIUM<|>GEO<|>The basal lamina of epithelium is a localization site for Urinary Bladder Cancer.)\n##\n(\"entity\"<|>EPITHELIUM<|>GEO<|>The epithelium is a tissue where Urinary Bladder Cancer can localize.)\n##\n(\"entity\"<|>PENIS<|>GEO<|>The penis is a localization site for Urinary Bladder Cancer.)\n##\n(\"entity\"<|>VAGINA<|>GEO<|>The vagina is another localization site for Urinary Bladder Cancer.)\n##\n(\"entity\"<|>SEMINAL VESICLE<|>GEO<|>The seminal vesicle can be affected by Urinary Bladder Cancer.)\n##\n(\"entity\"<|>VAS DEFERENS<|>GEO<|>The vas deferens is a localization site for Urinary Bladder Cancer.)\n\n(\"entity\"<|>MITOMYCIN<|>ORGANIZATION<|>Mitomycin is a compound used to treat Urinary Bladder Cancer, classified as an alkylating agent.)\n##\n(\"entity\"<|>VALRUBICIN<|>ORGANIZATION<|>Valrubicin is a compound that treats Urinary Bladder Cancer and does not belong to any specific pharmacologic class.)\n##\n(\"entity\"<|>GEMCITABINE<|>ORGANIZATION<|>Gemcitabine is a nucleic acid synthesis inhibitor used to treat Urinary Bladder Cancer.)\n##\n(\"entity\"<|>CARBOPLATIN<|>ORGANIZATION<|>Carboplatin is a platinum-containing compound used in the treatment of Urinary Bladder Cancer.)\n##\n(\"entity\"<|>FLUOROURACIL<|>ORGANIZATION<|>Fluorouracil is a nucleic acid synthesis inhibitor that treats Urinary Bladder Cancer.)\n##\n(\"entity\"<|>CISPLATIN<|>ORGANIZATION<|>Cisplatin is a platinum-containing compound used to treat Urinary Bladder Cancer.)\n##\n(\"entity\"<|>METHOTREXATE<|>ORGANIZATION<|>Methotrexate is a folic acid metabolism inhibitor used in the treatment of Urinary Bladder Cancer.)\n##\n(\"entity\"<|>ETOPOSIDE<|>ORGANIZATION<|>Etoposide is a topoisomerase inhibitor used to treat Urinary Bladder Cancer.)\n##\n(\"entity\"<|>THIOTEPA<|>ORGANIZATION<|>Thiotepa is an alkylating agent used in the treatment of Urinary Bladder Cancer.)\n##\n(\"entity\"<|>DOXORUBICIN<|>ORGANIZATION<|>Doxorubicin is a topoisomerase inhibitor used to treat Urinary Bladder Cancer.)\n\n(\"relationship\"<|>URINARY BLADDER CANCER<|>ANOREXIA<|>Anorexia is a symptom that presents in patients with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>URINARY BLADDER, NEUROGENIC<|>Neurogenic urinary bladder is a symptom associated with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>BODY WEIGHT<|>Changes in body weight are a symptom of Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>DIARRHEA<|>Diarrhea is a symptom that can occur in patients with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>EDEMA<|>Edema is a symptom that may present in individuals with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>FEVER<|>Fever is a common symptom associated with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>FLATULENCE<|>Flatulence is a symptom that may occur in patients with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>NAUSEA<|>Nausea is a symptom experienced by individuals with Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>PAIN, POSTOPERATIVE<|>Postoperative pain can be a symptom related to treatments for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>PARAPLEGIA<|>Paraplegia may be associated with complications from Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>LYMPH NODE<|>Lymph nodes are a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>URETER<|>The ureter is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>URETHRA<|>The urethra is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>FEMALE REPRODUCTIVE SYSTEM<|>The female reproductive system can be affected by Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>BASAL LAMINA OF EPITHELIUM<|>The basal lamina of epithelium is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>EPITHELIUM<|>The epithelium is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>PENIS<|>The penis is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>VAGINA<|>The vagina is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>SEMINAL VESICLE<|>The seminal vesicle can be affected by Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>URINARY BLADDER CANCER<|>VAS DEFERENS<|>The vas deferens is a localization site for Urinary Bladder Cancer<|>8)\n##\n(\"relationship\"<|>MITOMYCIN<|>URINARY BLADDER CANCER<|>Mitomycin is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>VALRUBICIN<|>URINARY BLADDER CANCER<|>Valrubicin is a compound that treats Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>GEMCITABINE<|>URINARY BLADDER CANCER<|>Gemcitabine is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>CARBOPLATIN<|>URINARY BLADDER CANCER<|>Carboplatin is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>FLUOROURACIL<|>URINARY BLADDER CANCER<|>Fluorouracil is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>CISPLATIN<|>URINARY BLADDER CANCER<|>Cisplatin is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>METHOTREXATE<|>URINARY BLADDER CANCER<|>Methotrexate is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>ETOPOSIDE<|>URINARY BLADDER CANCER<|>Etoposide is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>THIOTEPA<|>URINARY BLADDER CANCER<|>Thiotepa is a compound used to treat Urinary Bladder Cancer<|>9)\n##\n(\"relationship\"<|>DOXORUBICIN<|>URINARY BLADDER CANCER<|>Doxorubicin is a compound used to treat Urinary Bladder Cancer<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: [Urinary Bladder Cancer] is the name of a kind of disease.\n[Urinary Bladder Cancer] presents the symptom [Anorexia].\n[Urinary Bladder Cancer] presents the symptom [Urinary Bladder, Neurogenic].\n[Urinary Bladder Cancer] presents the symptom [Body Weight].\n[Urinary Bladder Cancer] presents the symptom [Diarrhea].\n[Urinary Bladder Cancer] presents the symptom [Edema].\n[Urinary Bladder Cancer] presents the symptom [Fever].\n[Urinary Bladder Cancer] presents the symptom [Flatulence].\n[Urinary Bladder Cancer] presents the symptom [Nausea].\n[Urinary Bladder Cancer] presents the symptom [Pain, Postoperative].\n[Urinary Bladder Cancer] presents the symptom [Paraplegia].\n[Urinary Bladder Cancer] localizes at the [Lymph Node] of human body.\n[Urinary Bladder Cancer] localizes at the [Ureter] of human body.\n[Urinary Bladder Cancer] localizes at the [Urethra] of human body.\n[Urinary Bladder Cancer] localizes at the [Female Reproductive System] of human body.\n[Urinary Bladder Cancer] localizes at the [Basal Lamina Of Epithelium] of human body.\n[Urinary Bladder Cancer] localizes at the [Epithelium] of human body.\n[Urinary Bladder Cancer] localizes at the [Penis] of human body.\n[Urinary Bladder Cancer] localizes at the [Vagina] of human body.\n[Urinary Bladder Cancer] localizes at the [Seminal Vesicle] of human body.\n[Urinary Bladder Cancer] localizes at the [Vas Deferens] of human body.\n\nThe following content describes information about compounds that can palliate or treat the disease named Urinary Bladder Cancer.The format of each compound's information is as follows:\nCompound name: ***\nPharmacologic class: ***\nEffect on Urinary Bladder Cancer: Palliate or Treat\nSide effect: ***\nThese respectively represent the name of the compound, the pharmacologic class it belongs to, its positive effect on the disease named Urinary Bladder Cancer (palliates or treats) and its side effects.\n\nCompound name: Mitomycin\nPharmacologic class: Alkylating Activity\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Alopecia, Anaemia, Anorexia, Asthenia, Confusional state, Cough, Dermatitis, Diarrhoea, Dizziness, Drowsiness\n\nCompound name: Valrubicin\nPharmacologic class: None\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Abdominal pain, Anaemia, Asthenia, Back pain, Chest pain, Cystitis, Dermatitis, Diarrhoea, Dizziness, Dysuria\n\nCompound name: Gemcitabine\nPharmacologic class: Nucleic Acid Synthesis Inhibitors\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Traffic accident, Agranulocytosis, Alopecia, Anaphylactic shock, Anaemia, Anorexia, Arrhythmia, Arthralgia, Asthenia, Azoospermia\n\nCompound name: Carboplatin\nPharmacologic class: Platinum-containing Compounds\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Infection, Extravasation, Body temperature increased, Pain, Phlebitis, Venous thrombosis, Fluid overload\n\nCompound name: Fluorouracil\nPharmacologic class: Nucleic Acid Synthesis Inhibitors\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Congenital anomaly, Abortion spontaneous, Agranulocytosis, Alopecia, Amnesia, Anaphylactic shock, Anaemia, Angina pectoris, Anorexia, Arrhythmia\n\nCompound name: Cisplatin\nPharmacologic class: Platinum-containing Compounds\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Abscess, Alopecia, Amnesia, Anaphylactic shock, Anaemia, Haemolytic anaemia, Anorexia, Anxiety, Arrhythmia, Asthenia\n\nCompound name: Methotrexate\nPharmacologic class: Folic Acid Metabolism Inhibitors\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Abdominal pain, Abscess, Agranulocytosis, Alopecia, Alveolitis allergic, Anaphylactic shock, Anaemia, Aplastic anaemia, Anaemia megaloblastic, Anorexia\n\nCompound name: Etoposide\nPharmacologic class: Topoisomerase Inhibitors\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Abdominal pain, Agranulocytosis, Alopecia, Anaphylactic shock, Anaemia, Anorexia, Apnoea, Ascites, Asthenia, Back pain\n\nCompound name: Thiotepa\nPharmacologic class: Alkylating Activity\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Abdominal pain, Agranulocytosis, Alopecia, Amenorrhoea, Anaemia, Anorexia, Anxiety, Arrhythmia, Arthralgia, Asthenia\n\nCompound name: Doxorubicin\nPharmacologic class: Topoisomerase Inhibitors\nEffect on Urinary Bladder Cancer: Treat\nSide effect: Abdominal distension, Abdominal pain, Abscess, Lactic acidosis, Agranulocytosis, Album\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}